DONG-A ST CO., LTD

Overview

• HeadquartersM5¹

See how the biggest companies compare on our leaderboards

Corporate structure

DONG-A ST CO., LTD sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

Calendar

Drug trials and FDA: coming up

1. Dec 2026Phase 2 trial readout expected Phase 2 trial of DA-2811 and DA-2811-C in Diabete Mellitus: primary completion expected Dec 2026 (ClinicalTrials.gov NCT07239440).²
2. Oct 2027Phase 4 trial readout expected Phase 4 trial of DA-9701 and DA-9701-R in Functional Dyspepsia: primary completion expected Oct 2027 (ClinicalTrials.gov NCT07686679).³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Stakes it holds

DONG-A ST CO., LTD has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

• MetaVia Inc.SCHEDULE 13D/A Sep 16, 2022 to May 20, 2025⁴